| The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity EYM Sum, B Peng, X Yu, J Chen, J Byrne, GJ Lindeman, JE Visvader Journal of Biological Chemistry 277 (10), 7849-7856, 2002 | 205 | 2002 |
| Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer MA Rubin, S Varambally, R Beroukhim, SA Tomlins, DR Rhodes, PL Paris, ... Cancer research 64 (11), 3814-3822, 2004 | 203 | 2004 |
| Improving the peer review of narrative literature reviews JA Byrne Research Integrity and Peer Review 1, 12, 2016 | 170 | 2016 |
| A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence JA Byrne, C Tomasetto, JM Garnier, N Rouyer, MG Mattei, JP Bellocq, ... Cancer research 55 (13), 2896-2903, 1995 | 158 | 1995 |
| Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting C Biesemann, M Grřnborg, E Luquet, SP Wichert, V Bernard, SR Bungers, ... The EMBO journal 33 (2), 157-170, 2014 | 157 | 2014 |
| MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells MC de Marco, F Martín-Belmonte, L Kremer, JP Albar, I Correas, ... The Journal of cell biology 159 (1), 37-44, 2002 | 151 | 2002 |
| Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma DR Carter, J Murray, BB Cheung, L Gamble, J Koach, J Tsang, S Sutton, ... Science translational medicine 7 (312), 312ra176-312ra176, 2015 | 135 | 2015 |
| Definition of the Tumor Protein D52 (TPD52) Gene Family through Cloning ofD52Homologues in Human (hD53) and Mouse (mD52) JA Byrne, MG Mattei, P Basset Genomics 35 (3), 523-532, 1996 | 123 | 1996 |
| Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer JA Byrne, RL Balleine, MS Fejzo, J Mercieca, YE Chiew, Y Livnat, ... International journal of cancer 117 (6), 1049-1054, 2005 | 109 | 2005 |
| The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma RL Balleine, MS Fejzo, P Sathasivam, P Basset, CL Clarke, JA Byrne Genes, Chromosomes and Cancer 29 (1), 48-57, 2000 | 107 | 2000 |
| Digital magic, or the dark arts of the 21st century—how can journals and peer reviewers detect manuscripts and publications from paper mills? JA Byrne, J Christopher FEBS letters 594 (4), 583-589, 2020 | 105 | 2020 |
| The tumor protein D52 family: many pieces, many puzzles R Boutros, S Fanayan, M Shehata, JA Byrne Biochemical and biophysical research communications 325 (4), 1115-1121, 2004 | 104 | 2004 |
| The formin INF2 regulates basolateral-to-apical transcytosis and lumen formation in association with Cdc42 and MAL2 R Madrid, JF Aranda, AE Rodríguez-Fraticelli, L Ventimiglia, ... Developmental cell 18 (5), 814-827, 2010 | 95 | 2010 |
| Identification of MAL2, a novel member of the mal proteolipid family, though interactions with TPD52-like proteins in the yeast two-hybrid system SHD Wilson, AM Bailey, CR Nourse, MG Mattei, JA Byrne Genomics 76 (1-3), 81-88, 2001 | 95 | 2001 |
| Identification of homo-and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system JA Byrne, CR Nourse, P Basset, P Gunning Oncogene 16 (7), 873-881, 1998 | 95 | 1998 |
| Short-term expansion of receptive fields in rat primary somatosensory cortex after hindpaw digit denervation JA Byrne, MB Calford Brain research 565 (2), 218-224, 1991 | 83 | 1991 |
| Overexpressed oncogenic tumor-self antigens: New vaccine targets RK Bright, JD Bright, JA Byrne Human vaccines & immunotherapeutics 10 (11), 3297-3305, 2014 | 74 | 2014 |
| Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52 JD Lewis, LA Payton, JG Whitford, JA Byrne, DI Smith, LB Yang, RK Bright Molecular cancer research 5 (2), 133-144, 2007 | 74 | 2007 |
| Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52 M Shehata, I Bieche, R Boutros, J Weidenhofer, S Fanayan, L Spalding, ... Clinical Cancer Research 14 (16), 5050-5060, 2008 | 73 | 2008 |
| Tumor protein D52 (TPD52) and cancer—oncogene understudy or understudied oncogene? JA Byrne, S Frost, Y Chen, RK Bright Tumor Biology 35, 7369-7382, 2014 | 72 | 2014 |
Robert K. BrightProfessor of Immunology and Molecular Microbiology, Texas Tech University Health Sciences CenterVerified email at ttuhsc.edu
